PT-141 Spray is a research-use-only preparation featuring PT-141, also known as bremelanotide, a synthetic cyclic peptide analog related to alpha-melanocyte-stimulating hormone (α-MSH). PT-141 is studied extensively in melanocortin receptor biology, peptide-receptor interactions, neurobiology, and cellular signaling. Helix Bio provides research materials for controlled laboratory and scientific applications. This spray-format product is intended exclusively for research and laboratory use and is not intended for human or veterinary administration.
HPLC certified
Independent analysis
Highest standard
Full traceability
PT-141, or bremelanotide, is a synthetic cyclic peptide belonging to the melanocortin family. Scientific literature describes bremelanotide as an agonist at multiple melanocortin receptor subtypes, including MC3R and MC4R. Research has examined its interactions with melanocortin receptors and downstream signaling pathways.
The compound has been studied in both laboratory and clinical research settings. Researchers investigating PT-141 may therefore encounter literature covering receptor pharmacology, neurobiology, peptide signaling, pharmacokinetics, and experimental models of sexual behavior.
PT-141 should not be confused with a general-purpose peptide reagent. Its activity is closely associated with melanocortin receptor biology, making receptor expression, ligand-receptor interactions, and downstream cellular signaling important areas for experimental investigation.
PT-141 is commonly identified as bremelanotide, a synthetic cyclic peptide analog of α-MSH. The compound has been investigated for activity at melanocortin receptor subtypes including MC3R and MC4R.
The precise concentration, volume, formulation components, and other specifications of the spray should be confirmed using the current product listing and applicable lot-specific documentation.
PT-141 is relevant to research involving:
Research has also examined bremelanotide in relation to neural pathways associated with sexual behavior and motivation. These findings provide scientific context but should not be interpreted as evidence that a research-use PT-141 spray is safe or effective for human use.
PT-141 and bremelanotide refer to the same research compound. Bremelanotide is the generic name used in scientific and regulatory literature, while PT-141 is a commonly used development designation.
The distinction becomes important when searching scientific literature because studies may use either term. Researchers looking for primary literature should consider both "PT-141" and "bremelanotide" when conducting database searches.
An important distinction exists between a research-use PT-141 spray and FDA-approved bremelanotide products.
The FDA-approved product Vyleesi contains bremelanotide and is a prescription drug supplied as a subcutaneous injection for a specific clinical indication. The FDA labeling identifies its approved dosage form and route as a subcutaneous injection.
A research-use PT-141 Spray from Helix Bio should not be represented as Vyleesi, as an equivalent pharmaceutical formulation, or as an FDA-approved product. The spray format described on this page is supplied for laboratory research only.
Researchers working with melanocortin signaling need clearly identified research materials that can be incorporated into controlled experimental protocols.
PT-141 is a well-characterized research subject with a substantial scientific literature covering receptor pharmacology, neurobiology, and experimental human studies. This makes the compound particularly relevant for researchers investigating how melanocortin receptor agonists interact with biological signaling systems.
Helix Bio states that its research catalog is supported by analytical verification, including HPLC purity assessment, mass-spectrometry identity confirmation, and batch-specific Certificates of Analysis. Researchers should review the actual documentation associated with the PT-141 Spray lot they receive rather than assuming a general catalog specification applies to every batch.
PT-141 Spray is intended for qualified researchers and organizations conducting legitimate laboratory or scientific research, including:
The product is not intended for personal use, self-administration, diagnosis, treatment, or veterinary applications.
| Specification | Details |
|---|---|
| Product Name | PT-141 Spray |
| Active Research Compound | PT-141 (Bremelanotide) |
| Compound Class | Synthetic cyclic melanocortin peptide |
| Research Category | Specialty & Hormonal Peptides |
| Product Format | Spray |
| Intended Use | Research and laboratory use only |
| Purity | Refer to current lot-specific COA |
| Concentration | Refer to current product specification |
| Volume | Refer to current product specification |
| Appearance | Refer to current product specification |
| Storage | Follow current product label and lot documentation |
| Packaging | Research-use product packaging |
| Lot Testing | Refer to applicable batch documentation |
| Manufacturer/Supplier | Helix Bio |
| Country of Origin | Not independently specified on the reviewed product information |
Helix Bio states that its catalog includes third-party HPLC and mass-spectrometry testing and batch-specific Certificates of Analysis. The exact analytical results for PT-141 Spray should be confirmed against the applicable lot documentation.
PT-141 is particularly relevant to experimental studies involving melanocortin receptors. Published literature identifies bremelanotide as an agonist of multiple melanocortin receptor subtypes, with MC4R receiving particular attention in neurobiological research.
Researchers may use PT-141 as a research ligand when investigating receptor activation, receptor distribution, downstream signaling, and ligand-receptor interactions.
Because PT-141 is a defined synthetic peptide, it can be relevant to experiments examining how peptide structure relates to receptor activity.
Potential research areas include:
Research has examined bremelanotide in relation to melanocortin receptors expressed within the central nervous system. Experimental literature has proposed mechanisms involving MC4R signaling and dopaminergic pathways, although the precise neurobiological mechanisms remain an active area of research.
PT-141 has been evaluated experimentally through different routes and study designs. Earlier research included intranasal administration studies, while the FDA-approved pharmaceutical form uses a subcutaneous injection.
These studies should not be used to infer the safety, pharmacokinetics, bioavailability, or biological performance of a particular research-use spray formulation.
PT-141 can serve as a research subject for examining signaling pathways associated with melanocortin receptors. This may include comparative investigations involving MC3R, MC4R, and related melanocortin receptor systems.
Reliable analytical information is important when a peptide is being used as a research reagent. Differences in peptide identity, purity, concentration, or formulation can influence experimental interpretation.
Helix Bio states that its research materials undergo HPLC testing for purity and mass spectrometry for identity and molecular-weight confirmation. The company also states that Certificates of Analysis are supplied with batches.
For PT-141 Spray, researchers should review the applicable documentation for:
No purity percentage, certification, or testing result should be assumed unless it is documented for the specific lot.
Storage requirements depend on the specific PT-141 Spray formulation and should be determined from the current product label and lot documentation.
General laboratory handling practices include:
Helix Bio's website presents its catalog as research and laboratory materials and describes third-party analytical testing and batch-specific documentation. Current shipping policies and product availability should be reviewed directly before ordering.
Researchers should inspect received materials for appropriate labeling, packaging integrity, lot identification, and accompanying documentation.
Specific delivery conditions, packaging configuration, and shipping timelines may vary and should not be assumed unless stated in the current Helix Bio policies.
For Research Use Only. Not for Human or Veterinary Use.
PT-141 Spray is supplied solely as a research and laboratory material. It is not intended for human administration, veterinary administration, ingestion, inhalation, diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition.
PT-141/bremelanotide should not be confused with an FDA-approved pharmaceutical product. The FDA-approved bremelanotide product Vyleesi is a specific prescription drug formulation administered by subcutaneous injection for a defined clinical indication. The existence of an approved pharmaceutical formulation does not establish that this research-use PT-141 Spray is equivalent, interchangeable, safe, or approved for human use.
Helix Bio states that its products are offered for research and laboratory purposes only and are not intended to diagnose, treat, cure, or prevent disease.
Researchers are responsible for determining whether the material is appropriate for their specific experimental protocol and for complying with applicable institutional, federal, state, and local requirements.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Check a peptide COA against the vial label, the issuing lab's own record, and supplier claims. 12 red flags, what to request, and what stays uncertain.
Eloralintide (LY3841136) research explained: AMY1R mechanism, Phase 1/2 trial data, safety signals, EloraTZP combination evidence, and current FDA status.
What bacteriostatic water contains, how it differs from sterile water and saline, where the 28-day opened-vial figure comes from, and what a COA can show.
